1 . Report of UK Collaborative Study on Alpha-fetoprotein in relation to neural tube defects (1977)

ReportReport

2 . Maternal serum alpha-fetoprotein and diabetes mellitus (1979)

BookBook

Wald NJ, Cuckle H, Boreham J, Stirrat GM, Turnbull AC

3 . Chromosomal abnormality rates at amniocentesis and in live-born infants (1983)

PaperPaper

Hook EB, Cross PK, Schreinemachers DM

4 . A collaborative study of the segregation of inherited chromosome structural rearrangements in 1356 prenatal diagnoses (1984)

PaperPaper

Boué A, Gallano P

5 . The impact of screening for open neural tube defects in England and Wales (1987)

PaperPaper

Cuckle H, Wald N

6 . Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level (1987)

PaperPaper

Cuckle HS, Wald NJ, Thompson SG

7 . Maternal serum screening for Down's syndrome in early pregnancy (1988)

ArticleArticle

Wald NJ, Cuckle HS, Densem JW, Nanchahal K et al.

8 . Amniotic fluid acetylcholinesterase measurement in the prenatal diagnosis of open neural tube defects (1988)

PaperPaper

Wald N, Cuckle H, Nanchahal K

9 . Screening for Down's syndrome (1990)

PaperPaper

Cuckle HS, Wald NJ

10 . Maternal serum alpha-fetoprotein screening for open neural tube defects in twin pregnancies (1990)

PaperPaper

Cuckle H, Wald N, Stevenson JD, May HM et al

11 . Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome (1991)

PaperPaper

Wald N, Cuckle H, Wu T, George L.

12 . Antenatal maternal serum screening for Down's syndrome: results of a demonstration project (1992)

PaperPaper

Wald NJ, Kennard A, Densem JW, Cuckle HS, Chard T, Butler L

13 . Maternal serum screening for Down's syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight (1992)

PaperPaper

Wald NJ, Cuckle HS, Densem JW, Kennard A, Smith D

14 . Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome (1992)

PaperPaper

Wald NJ, Cuckle HS, Densem JW, Stone RB

15 . Maternal serum Free-ß human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome (1994)

PaperPaper

Wald NJ, Densem JW

16 . Four-marker serum screening for Down's syndrome (1994)

PaperPaper

Wald NJ, Densem JW, Smith D, Klee GG

17 . Repeat maternal serum testing for Down's syndrome screening using multiple markers with special reference to Free α and Free ß-hCG (1995)

PaperPaper

Hackshaw AK, Densem J, Wald NJ

18 . Detection of pregnancies with trisomy 18 in screening programmes for Down's syndrome (1995)

PaperPaper

Hackshaw AK, Kennard A, Wald NJ

19 . Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated estriol and human chorionic gonadotropin (1995)

PaperPaper

Palomaki GE, Haddow JE, Knight GJ, Wald NJ et al

20 . Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation (1995)

PaperPaper

Pandya PP, Snijders RJM, Johnson SP, de Lourdes Brizot M, Nicolaides KH

21 . Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy (1996)

PaperPaper

Wald NJ, George L, Smith D, Densem JW, Petterson K

22 . Prenatal screening for Down's syndrome using Inhibin-A as a serum marker (1996)

PaperPaper

Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG

23 . Effect of allowing for ethnic group in prenatal screening for Down's syndrome (1996)

PaperPaper

Watt HC, Wald NJ, Smith D, Kennard A, Densem J

24 . Maternal serum inhibin-A in pregnancies with insulin-dependent diabetes mellitus: implications for screening for Down's syndrome (1996)

PaperPaper

Wald NJ, Watt HC, George L

25 . Maternal serum inhibin-A levels in twin pregnancies: implications for screening for Down's syndrome (1996)

PaperPaper

Watt HC, Wald NJ, George L

26 . Refinements in managing maternal weight adjustment for interpreting prenatal screening results (1996)

PaperPaper

Neveux LM, Palomaki GE, Larrivee DA, Knight GJ, Haddow JE

27 . Inhibin-A in Down's syndrome pregnancies: revised estimate of standard deviation (1997)

PaperPaper

Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG, Watt H, Hacksaw A, Morris JK.

28 . Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome (1997)

PaperPaper

Wald NJ, Hackshaw AK

29 . Antenatal Screening for Down’s syndrome (1997)

PaperPaper

Wald NJ, Kennard A, Hackshaw A, McGuire A

30 . Empirical validation of risk screening for Down's syndrome (1996)

PaperPaper

Wald NJ, Hackshaw AK, Huttly W, Kennard A

31 . The distribution of nuchal translucency at 10-13 weeks of pregnancy (1998)

PaperPaper

Schuchter K, Wald N, Hackshaw AK, Hafner E, Liebhart E

32 . Screening for Down syndrome at 14 weeks of pregnancy (1998)

PaperPaper

Wald NJ, Watt HC, Haddow JE, Knight GJ

33 . The accuracy of assigned risks in maternal serum screening (1998)

PaperPaper

Canick JA, Rish S.

34 . Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Optiz (RSH) syndrome fetuses (1999)

PaperPaper

Bradley LA, Palomaki GE, Knight GJ et al.

35 . Fetal loss in Down syndrome pregnancies (1999)

PaperPaper

Morris JK, Wald NJ, Watt HC

36 . Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β-hCG and PAPP-A at 10-14 weeks of gestation (1999)

PaperPaper

Tul N, Spencer K, Noble P, Chan C, Nicolaides K

37 . Validation of risk estimation using the quadruple test in prenatal screening for Down syndrome (1999)

PaperPaper

Wald NJ, Huttly WJ.

38 . Integrated screening for Down's syndrome based on tests performed during the first and second trimesters (1999)

PaperPaper

Wald NJ, Watt HC, Hackshaw AK

39 . Serum markers for Down's syndrome in women who have had in vitro fertilisation: implications for antenatal screening (1999)

PaperPaper

Wald NJ, White N, Morris JK, Huttly WJ, Canick JA.

40 . Neural tube defects (2000)

ChapterChapter

Wald N

41 . Assay precision of serum α fetoprotein in antenatal screening for neural tube defects and Down's syndrome (2000)

PaperPaper

Wald NJ, Hackshaw AK, George LM

42 . Revised distribution parameters for serum markers for trisomy 18 (2005)

PaperPaper

Hackshaw AK, Wald NJ

43 . Screening for trisomy 21 in twin pregnancies in the first trimester using free β-hCG and PAPP-A, combined with fetal nuchal translucency thickness (2000)

PaperPaper

Spencer K

44 . Repeat testing in antenatal screening for Down syndrome using dimeric inhibin-A in combination with other maternal serum markers (2001)

PaperPaper

Hackshaw AK, Wald NJ

45 . Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance (2002)

PaperPaper

Rudnicka AR, Wald NJ, Huttly W, Hackshaw AK

46 . Revised estimates of the maternal age specific live birth prevalence of Down’s syndrome (2002)

PaperPaper

Morris JK, Mutton DE, Alberman E

47 . Assigning risk for Smith-Lemli-Opitz syndrome as part of 2nd trimester screening for Down's syndrome (2002)

PaperPaper

Palomaki GE, Bradley LA, Knight GJ, Craig WY, Haddow JE

48 . Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies (2005)

PaperPaper

Wald NJ, Rish S, Hackshaw AK

49 . First and second trimester antenatal screening for Down’s syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS) (2003)

PaperPaper

Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM

50 . Prenatal screening for Down’s syndrome: the problem of recurrent false-positives (2004)

PaperPaper

Wald NJ, Huttly WJ, Rudnicka AR

51 . SURUSS in perspective (2004)

PaperPaper

Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A

52 . Likelihood ratio for trisomy 21 in fetuses with absent nasal bone at the 11-14 week scan (2004)

PaperPaper

Cicero S, Rembouskos G, Vandecruys H, Hogg M, Nicolaides KH

53 . Nuchal translucency and gestational age (2004)

PaperPaper

Wald N, Rodeck C, Rudnicka A, Hackshaw A

54 . Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus (2004)

PaperPaper

Huttly W, Rudnicka A, Wald NJ

55 . Graphical presentation of distributions of risk in screening (2005)

PaperPaper

Morris JK, Wald NJ

56 . Corrections to maternal age-specific live birth prevalence of Down's syndrome (2005)

PaperPaper

Morris J, Mutton D, Alberman E

57 . Which gestational age estimate to use in AFP screening for spina bifida? (2005)

PaperPaper

Wald NJ

58 . Prenatal screening for Down syndrome and neural tube defects in twin pregnancies (2005)

PaperPaper

Wald NJ, Rish S

59 . Correction to SURUSS report (2006)

PaperPaper

Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM, Bestwick JP

60 . Effect on Down syndrome screening performance of adjusting for marker levels in a previous pregnancy (2006)

PaperPaper

Wald NJ, Barnes IM, Birger R, Huttly W

61 . Recurrences of free Trisomy 21: analysis of the data from the National Down Syndrome Cytogenetic Register (2006)

PaperPaper

Morris KJ, Mutton DE, Alberman E

62 . Inhibin-A regression (1999)

PaperPaper

Watt HC, Wald NJ, Huttly WJ

63 . New charts for ultrasound dating of pregnancy (1997)

PaperPaper

Altman DG and Chitty LS

64 . Sequential and contingent prenatal screening for Down syndrome (2006)

PaperPaper

Wald NJ, Rudnicka AR and Bestwick JP

65 . Anomalous marker patterns in Down syndrome screening (2007)

PaperPaper

Wald NJ, Bestwick JP, Barnes IM, Kellner LH

66 . Maternal serum invasive trophoblast antigen (ITA) in first trimester trisomy 18 pregnancies (2005)

PosterPoster

Palomaki G, Knight G, Neveux L, Pandian R, Haddow J

67 . Validation plots in antenatal screening for Down’s syndrome (2006)

PaperPaper

Wald NJ, Bestwick JP, Huttly WJ, Morris JK and George LM

68 . Inhibin-A concentrations between 14 and 22 weeks of gestation (2008)

PaperPaper

Wald NJ, Bestwick JP, Huttly WJ

69 . First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotophin, pregnancy-assisted plasma protein-A and nuchal translucency (2008)

PaperPaper

Bestwick JP, Huttly WJ, Wald NJ

70 . Maternal serum unconjugated oestriol as an antenatal screening test for Down’s syndrome (1988)

PaperPaper

Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Canick JA, Haddow JE, Knight GJ and Palomaki GE

71 . Adjustment of serum markers in first trimester screening (2009)

PaperPaper

Lambert-Messerlian G, Palomaki GE and Canick JA

72 . Fetal size and dating: charts recommended for clinical obstetric practice (2009)

PaperPaper

Loughna P, Chitty L, Evans T, Chudleigh T

73 . Recent advances in screening for neural tube defects and Down’s syndrome (1987)

PaperPaper

Wald NJ and Cuckle HS

74 . Estimating the risk of Down's syndrome in antenatal screening and the gestation at which this risk applies (2007)

PaperPaper

Morris JK and Wald NJ

75 . Distribution of nuchal translucency in antenatal screening for Down’s syndrome (2010)

PaperPaper

J P Bestwick, WJ Huttly and N J Wald

76 . Maternal serum alphafetoprotein screening for open neural tube defects: revised statistical parameters (2000)

PaperPaper

NJ Wald, AK Hackshaw and HS Cuckle

77 . A critical evaluation of crown rump length measurements (1975)

PaperPaper

HP Robinson and JE Fleming

78 . Estimating an individual's risk of having a fetus with open spina bifida and the value of repeat alpha fetoprotein testing. Fourth Report of the U.K. Collaborative Study on Alpha fetoprotein in Relation to Neural Tube Defects (1982)

PaperPaper

NJ Wald, HS Cuckle

79 . Small biparietal diameter of fetuses with spina bifida: implications for antenatal screening (1980)

PaperPaper

NJ Wald, HS Cuckle, J Boreham, G Stirrat

80 . Screening in early pregnancy for pre-eclampsia using Down syndrome Quadruple test markers (2006)

PaperPaper

Wald NJ, Morris JK, Ibison J, Wu T and George L

81 . Ductus venosus pulsatility index as an antenatal screening marker for Down’s syndrome: use with the Combined and Integrated tests (2009)

PaperPaper

Borrell A, Borobio V, Bestwick JP and Wald NJ

82 . Screening for trisomy 18 and trisomy 13 using first and second trimester Down syndrome screening markers (2013)

PaperPaper

JP Bestwick, WJ Huttly and NJ Wald

83 . The maternal age-specific live birth prevalence of trisomies 13 and 18 compared to trisomy 21 (Down syndrome) (2010)

PaperPaper

GM Savva, K Walker, JK Morris

84 . The risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18 (2005)

PaperPaper

JK Morris, GM Savva

85 . Unconjugated estriol values between 14 and 22 weeks of gestation in relation to prenatal screening for Down syndrome (2012)

PaperPaper

JP Bestwick, WJ Huttly and NJ Wald

86 . Adding ductus venosus blood flow as a categorical variable to the Combined and Integrated tests in Down’s syndrome screening (2012)

PaperPaper

NJ Wald, JP Bestwick and A Borelli

87 . The estimation of gestational age of pregnancy for use in screening for Down’s syndrome using ultrasound measurements and embryo transfer date (2012)

PaperPaper

WJ Huttly and NJ Wald

88 . Seeking other disorders within antenatal serum screening programmes for Down's syndrome (2002)

paperpaper

Wald NJ and Canick JA

89 . Improvements in antenatal screening for Down’s syndrome (2013)

paperpaper

NJ Wald, JP Bestwick and WJ Huttly

90 . Screening for pre-eclampsia using serum placental growth factor and endoglin measurement with Down’s Syndrome Quadruple test markers (2012)

paperpaper

NJ Wald, JP Bestwick, LM George, T Wu and J Morris

91 . Maternal illness and drug use in pregnancy (1992)

bookbook

JM Elwood, J Little and JH Elwood

92 . Antenatal Screening for Down Syndrome Using Serum Placental Growth Factor with the Combined, Quadruple, Serum Integrated and Integrated Tests

paperpaper

NJ Wald, JP Bestwick, LM George and W J Huttly

93 . The use of free beta-hCG in antenatal screening for Down's syndrome (1993)

paperpaper

Wald NJ, Densem J, Stone R, Cheng

94 . Prediction of early intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks (2011)

paperpaper

Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.

95 . Competing risks model in early screening for preeclampsia by biophysical and biochemical markers (2013)

paperpaper

Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH.

96 . Epidemiological clues to the causation of neural tube defects.

bookbook

Leck I

97 . Allowing for ethnic group in antenatal screening for Down’s syndrome (2013)

articlearticle

Bestwick JP, Huttly WJ and Wald NJ

98 . Effect of smoking status on inhibin-A in second trimester prenatal screening for Down syndrome (2014)

articlearticle

Huttly WJ, Bestwick J and Wald NJ

99 . The estimation of median nuchal translucency values between 10 and 14 weeks of pregnancy (2014)

articlearticle

Bestwick JP, Huttly WJ, Wald NJ

100 . Prevalence and risk of Down syndrome in monozygotic and dizygotic multiple pregnancies in Europe: implications for prenatal screening. (2014)

articlearticle

99. Boyle B, Morris JK, McConkey R, Garne E, Loane M, Addor MC, Gatt M, Haeusler M, Latos-Bielenska A, Lelong N, McDonnell R,Mullaney C, O’Mahony M.

101 . Antenatal screening for Down’s syndrome, trisomy 18, and trisomy 13: Reporting a single screening result for all three (2015)

articlearticle

Bestwick JP and Wald NJ

102 . First trimester maternal serum AFP and total hCG in aneuploidies other than trisomy 21 (2000)

articlearticle

Spencer K, Heath V, Flack N, Ong C and Nicolaides KH

103 . Sequential Integrated antenatal screening for Down’s syndrome, trisomy 18 and trisomy 13 (2015)

articlearticle

Bestwick J, Wald NJ

104 . Incorporating DNA Sequencing into Current Prenatal Screening Practice for Down’s Syndrome (2013)

articlearticle

Wald NJ, Bestwick JP

105 . Performance of antenatal reflex DNA screening for Down’s syndrome (2015)

articlearticle

Wald NJ, Bestwick JP

106 . Insulin dependent diabetes mellitus (IDDM) and first trimester markers in prenatal screening for Down syndrome (2016)

articlearticle

Huttly WJ, Bestwick JP and Wald NJ

107 . Fetal crown-rump length: reevaluation of relation to menstrual age ( 5-18 weeks) with high- Resolution real time US (1992)

articlearticle

Hadlock FP, Shah YP, Kanon DJ, Lindsey JV

108 . Pregnancy Associated Plasma Protein-A Truncation Limits in Antenatal Screening for Trisomy 18 (2018)

articlearticle

Bestwick JP, Huttly WJ, Wald NJ,

109 . Prenatal reflex DNA screening for trisomy 21, 18, and 13 (2017)

articlearticle

Wald NJ, Huttly WJ, Bestwick JP, Robert Old, Joan K Morris, Ray Cheng, Joe Aquilina, Elisabeth Peregrine, Devender Roberts, Zarko Alfirevic

110 . DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. (2011)

articlearticle

Palomaki GE, Kloza EM, Lambert-Messerlian GM et al

111 . Fetal crown–rump length and estimation of gestational age in an ethnic Chinese population (2009)

articlearticle

Sahota, DS, Leung, TY, Leung, TN, Chan, OK and Lau, TK

112 . Serum marker truncation limits in first trimester antenatal screening for trisomy 18. (2018)

PaperPaper

Bestwick JP, Huttly WJ and Wald NJ

113 . Prenatal screening for Down syndrome in twin pregnancies: Estimates of screening performance based on 61 affected and 7302 unaffected twin pregnancies (2018)

paperpaper

Wald NJ, Bestwick JP, Huttly WJ, Aldis J, Borrell A, Goodburn S & Mills I

114 . Corrigendum for Wald NJ, Bestwick JP, Huttly WJ, Aldis J, Borrell A, Goodburn S & Mills I (2018) https://doi.org/10.1002/pd.5381 (2019)

paperpaper

Wald NJ, Bestwick JP, Huttly WJ, Aldis J, Borrell A, Goodburn S & Mills I

115 . First trimester maternal serum placental growth factor levels in twin pregnancies (2013)

PaperPaper

Cowans NJ and Spencer K

116 . Antenatal screening for Down’s Syndrome: Revised nuchal translucency upper truncation limit due to improved precision of measurement (2020)

PaperPaper

Vale SH, Huttly WJ and Wald NJ